CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Sumatriptan 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02741310
NCT02741310Phase 1Completed
CompareCT.gov

Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex™) in Healthy Subjects

Amgen·interventional·Posted Apr 18, 2016·Updated Apr 2, 2019

In Brief

A Phase 1 clinical trial evaluating Placebo, Sumatriptan, and 1 other intervention for Healthy Subjects. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The primary objective of this study was to assess the effects of subcutaneous sumatriptan alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan concomitant therapy on resting blood pressure in healthy adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 18, 2016
Enrollment StartFeb 22, 2016
Primary CompletionAug 11, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.2 years ago

Interventions

Placebodrug

Administered by intravenous infusion

Sumatriptandrug

Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5

Erenumabdrug

Administered by intravenous infusion